NASDAQ:PLUR Pluri (PLUR) Stock Price, News & Analysis $5.65 +0.04 (+0.71%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range$5.10▼$5.7050-Day Range$4.68▼$6.6052-Week Range$3.45▼$8.48Volume3,736 shsAverage Volume17,577 shsMarket Capitalization$30.44 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get Pluri alerts: Email Address Ad Crypto 101 MediaNext opportunity for crypto millionsThe Bitcoin halving is the #1 creator of "crypto millionaires". That's because historically, every halving has led to a massive bull run in the year after it happens. That means we're in the "golden window" right now…Check out the new "Crypto Bull Run Millionaire Blueprint" now! About Pluri Stock (NASDAQ:PLUR)Pluri Inc., a biotechnology company, engages in the development of placenta-based cell therapy product candidates for the treatment of inflammatory, muscle injuries, and hematologic conditions. It operates in the field of regenerative medicine, food-tech, and biologics and focuses on establishing partnerships that leverage its 3D cell-based technology to additional industries that require mass cell production. The company's development pipeline includes PLX-PAD, is composed of maternal mesenchymal stromal cells originating from the placenta that is currently under phase III study for orthopedic, phase II study for COVID-19, and phase I/II clinical study for Steroid-Refractory cGVHD indications; and PLX-R18, is composed of fetal MSC like cells originating from the placenta that is currently under phase I study for HCT and pilot study for ARS indications. It is also involved in the development of modified PLX cells. The company was formerly known as Pluristem Therapeutics Inc. and changed its name to Pluri Inc. in July 2022. Pluri Inc. was incorporated in 2001 and is based in Haifa, Israel.Read More PLUR Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart PLUR Stock News HeadlinesJuly 27 at 1:14 AM | americanbankingnews.comCritical Survey: Tevogen Bio (NASDAQ:TVGN) versus Pluri (NASDAQ:PLUR)July 20, 2024 | msn.comHalf of LGBTQ+ professionals have experienced depression & few feel they can be “authentic” at workJuly 27, 2024 | Behind the Markets (Ad)J.P. Morgan’s DIRE WarningWhen the largest bank in the U.S. says a crisis is coming - you NEED to listen. The Wall Street Journal warns, "America's bonds are getting harder to sell."July 18, 2024 | globenewswire.comPluri's CDMO Selected to Manufacture Kadimastem's Novel Cell Therapy Product CandidatesJune 18, 2024 | globenewswire.comPluri Subsidiary Ever After Foods Secured $10 Million Strategic Investment to Solve Cultivated Food Scalability ChallengesJune 6, 2024 | globenewswire.comU.S. National Institutes of Health Exercises Option to Fund $1.4 Million 2nd Year Budget for Pluri's PLX-R18 Acute Radiation Syndrome ContractMay 20, 2024 | globenewswire.comNovel Medical Food Solution for the Elderly: Pluri & Wilk Collaborate to Develop Human Breast Milk-Derived Food Production on a Commercial ScaleMay 12, 2024 | finance.yahoo.comPluri Third Quarter 2024 Earnings: US$1.01 loss per share (vs US$1.53 loss in 3Q 2023)July 27, 2024 | Behind the Markets (Ad)J.P. Morgan’s DIRE WarningWhen the largest bank in the U.S. says a crisis is coming - you NEED to listen. The Wall Street Journal warns, "America's bonds are getting harder to sell."May 2, 2024 | globenewswire.comUnleashing the Power of MAIT Cells: Pluri Launches Novel Immunotherapy Platform for Solid Tumor Cancer TreatmentApril 11, 2024 | msn.comPackers will face the Eagles in Brazil's first NFL game everApril 10, 2024 | uk.investing.comPluri Inc. announces breakthrough in immune cell therapy productionApril 8, 2024 | msn.comPluri stock jumps 9% on US patent for immune cell productionApril 8, 2024 | globenewswire.comBreakthrough in Immune Cell Expansion: Pluri Granted U.S Patent for New MethodApril 3, 2024 | investorplace.comPLUR Stock Earnings: Pluri Reported Results for Q4 2023March 29, 2024 | msn.comReAlta signs deal with NIAID to develop drug for radiation poisoningMarch 28, 2024 | finance.yahoo.comPluri’s Business Verticals Gain Traction in Global Markets; Leadership to Participate and Present in Upcoming ConferencesMarch 28, 2024 | globenewswire.comPluri's Business Verticals Gain Traction in Global Markets; Leadership to Participate and Present in Upcoming ConferencesSee More Headlines Receive PLUR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Pluri and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/09/2024Today7/26/2024Next Earnings (Estimated)9/10/2024Fiscal Year End6/30/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:PLUR CUSIPN/A CIK1158780 Webpluri-biotech.com Phone972747108600Fax972-74-710-8787Employees150Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($4.13) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-28,320,000.00 Net Margins-6,339.59% Pretax Margin-6,477.42% Return on Equity-248.48% Return on Assets-49.90% Debt Debt-to-Equity Ratio13.04 Current Ratio6.05 Quick Ratio6.05 Sales & Book Value Annual Sales$290,000.00 Price / Sales104.97 Cash FlowN/A Price / Cash FlowN/A Book Value$2.97 per share Price / Book1.90Miscellaneous Outstanding Shares5,390,000Free Float4,839,000Market Cap$30.44 million OptionableOptionable Beta1.65 The 10 Best AI Stocks to Own in 2024Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free Report Key ExecutivesMr. Yaacov Yanay (Age 53)President, CEO & Director Comp: $575.93kMs. Chen Franco-Yehuda (Age 40)CFO, Treasurer & Secretary Comp: $375.24kMr. Lior RavivChief Technology OfficerMs. Efrat Livne-HadassVice President of Human ResourcesDr. Nitsan Halevy M.D.Chief Medical OfficerMr. Nimrod Bar ZviChief Commercial OfficerMore ExecutivesKey CompetitorsVaxartNASDAQ:VXRTCybinNYSE:CYBNI-MabNASDAQ:IMABKaryopharm TherapeuticsNASDAQ:KPTICellectisNASDAQ:CLLSView All CompetitorsInstitutional OwnershipValues First Advisors Inc.Sold 96,553 shares on 7/19/2024Ownership: 0.265%View All Institutional Transactions PLUR Stock Analysis - Frequently Asked Questions How have PLUR shares performed this year? Pluri's stock was trading at $4.6360 on January 1st, 2024. Since then, PLUR stock has increased by 21.8% and is now trading at $5.6480. View the best growth stocks for 2024 here. How were Pluri's earnings last quarter? Pluri Inc. (NASDAQ:PLUR) issued its earnings results on Thursday, May, 9th. The company reported ($1.01) earnings per share (EPS) for the quarter. The company had revenue of $0.07 million for the quarter. Pluri had a negative trailing twelve-month return on equity of 248.48% and a negative net margin of 6,339.59%. When did Pluri's stock split? Pluri's stock reverse split before market open on Monday, April 1st 2024. The 1-8 reverse split was announced on Monday, April 1st 2024. The number of shares owned by shareholders was adjusted after the closing bell on Monday, April 1st 2024. An investor that had 100 shares of stock prior to the reverse split would have 13 shares after the split. Who are Pluri's major shareholders? Top institutional shareholders of Pluri include Values First Advisors Inc. (0.27%). View institutional ownership trends. How do I buy shares of Pluri? Shares of PLUR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:PLUR) was last updated on 7/27/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredRare signal predicts 50% market drop - before electionThe market is near all-time highs, we're told that unemployment is low, AI's a gift to humanity, and the FED w...Behind the Markets | SponsoredThis student turned $1,300 into $45,000 in just 4 Months!With the help of S.A.M. (my new AI-powered scanner) it's now easier than ever to find these unique trades... ...Monument Traders Alliance | SponsoredCollapse of the PetrodollarThe death of the "petrodollar" seems imminent. And the implications could not be worse for Americans. Ru...Colonial Metals | SponsoredFormer Hedge Fund Manager Issues Crash PredictionOur No. 1 stock for the rare "millionaire window" opening NOW According to Wall Street legend Whitney Tilso...Stansberry Research | SponsoredBrace Yourself: Experts calling for Bitcoin to hit $100kFor the past few months, Bitcoin has been trading flat… It's been stuck around the $60,000 to $72,000 range...Crypto 101 Media | SponsoredBreaking News: Elon Musk Invents New Type of A.I. (Shocking)Could Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Pluri Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Pluri With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.